Riyadh, April 27, 2025, SPA -- The Saudi Ports Authority (Mawani) has signed an agreement with Alissa Universal Motors, a subsidiary of Abdullatif Alissa Group Holding, to establish a logistics park ...

In trading on Thursday, shares of ATI Inc (Symbol: ATI) crossed above their 200 day moving average of $58.29, changing hands as high as $60.85 per share. ATI Inc shares are currently trading up ...

ATI Price Performance ATI stock opened at $53.85 on Tuesday. The company has a market cap of $7.60 billion, a price-to-earnings ratio of 21.12, a PEG ratio of 0.85 and a beta of 0.80. The firm’s ...

Earlier this month, a Trump administration plan to cut the National Institutes of Health budget by more than 40% was leaked to the press. The preliminary budget sent shockwaves through the nation ...

Bangladeshi artistes are set to perform in Dammam, Saudi Arabia, as part of the "Passport to the World" cultural festival, an extension of the annual "Riyadh Season" initiated by the Saudi ...

Unionized workers at ATI ratified a six-year contract Tuesday. The deal between the manufacturer and the United Steelworkers covers about 1,200 workers at its facilities, including 66 at ATI's ...

ATI and its employees have reached a six-year labor agreement. The deal was announced Wednesday, about a week after ATI and the United Steelworkers union reached a tentative agreement on wages ...

Fields, ATI President and CEO. The new agreement delivers a competitive wage and benefit package to nearly 1,000 represented employees, covering a six-year term through February 28, 2031.

A new contract has been ratified between ATI and the United Steelworkers Union according to an announcement late Tuesday night. In a statement from ATI, its employees have "ratified a new six-year ...

The project covers the construction of a new freight yard and freight line connecting Dammam’s Second Industrial City with the existing 556km-long Dammam-Riyadh railway Register for MEED’s 14-day ...

The US Food and Drug Administration (FDA) has approved an investigational new drug (IND) application from Aclaris Therapeutics, allowing the company to begin a placebo-controlled Phase Ia/Ib study of ...